What you want to know:

– Dandelion Well being, a real-world information (RWD) and scientific AI platform, right now introduced research findings displaying that GLP-1 medicine could also be efficient in stopping heart problems (CVD) in a considerably bigger inhabitants than beforehand thought.

– This analysis, carried out utilizing validated AI on Dandelion’s not too long ago launched Medical AI Market, opens the door to a brand new period of precision medication and personalised care in cardiometabolic illness.

Unveiling the Medical AI Market

Dandelion’s Medical AI Market is a revolutionary platform that allows life sciences organizations to speed up and optimize scientific analysis. By leveraging AI algorithms and sturdy RWD, researchers can quickly generate new insights in a fraction of the time and value of conventional scientific trials.

The ability of unstructured information

Conventional RWD is usually restricted to structured information, leaving a wealth of beneficial data locked away in unstructured codecs equivalent to picture information, waveforms, and scientific notes. Dandelion’s Market breaks down these information silos and unlocks important insights into therapy discontinuation, signs, and therapy response, enabling a deeper understanding of affected person journeys.

Extending the attain of GLP-1s

Dandelion's research, carried out in simply six weeks, addressed an vital query not addressed in scientific trials: Can GLP-1s be used as a main preventative for coronary heart assaults and strokes in people with out critical heart problems?

Utilizing AI biomarkers and its GLP-1 information library, Dandelion examined a wider inhabitants than that studied in scientific trials. Findings recommend that GLP-1s might lead to a 15%–20% decrease danger of main hostile cardiovascular occasions (MACE) on this beforehand unstudied group, probably benefiting a further 44 million sufferers.

AI: Accelerating scientific analysis and bettering affected person care

Dandelion’s method demonstrates how AI can de-risk and speed up scientific analysis, enabling life sciences corporations to make knowledgeable choices about scientific trials, therapy comparisons, and market entry. Moreover, these insights allow suppliers to make personalised therapy selections, resulting in earlier interventions and higher affected person outcomes.

“The mixed energy of real-world information and AI has the potential to remodel the way in which life sciences conduct scientific trials and analysis,” stated Shivaani Prakash, MSc, PhD, Head of Information at Dandelion Well being. “By combining various, multi-modal information with validated AI, life sciences corporations and researchers can now research therapy results on a a lot bigger, extra consultant inhabitants — at a fraction of the price and time.”